Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Feb 12, 2014
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Exercise/Conversion
Common Stock, no par value
2014-02-11+11,000→ 103,823 total - Tax Payment
Common Stock, no par value
2014-02-11−5,707→ 98,116 total - Exercise/Conversion
Restricted Share Units
2014-02-11−11,000→ 11,000 total→ Common Stock (11,000 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $62.62 starting on January 28, 2013 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
- [F2]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.